First-in-human results prompt a biomarker-defined approach for CID-078.
ApexOnco Front Page
Recent articles
AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
The latest Chinese pivotal study of iza-bren will be in first-line small-cell lung cancer.
A $3.15bn deal follows a December 2024 option agreement.
The groups spend big on Terns and Arcellx.
Rinzimetostat efficacy wanes further as the company moves into phase 3.
J&J’s Tecvayli/Darzalex nod was the second under a new priority voucher scheme.
Replimune gets a second chance, while Sarclisa could go subcutaneous.
